Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02293863
Registration number
NCT02293863
Ethics application status
Date submitted
14/11/2014
Date registered
18/11/2014
Date last updated
18/06/2018
Titles & IDs
Public title
A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection
Query!
Scientific title
Query!
Secondary ID [1]
0
0
2014-000461-43
Query!
Secondary ID [2]
0
0
GV29216
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Influenza
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - MHAA4549A
Treatment: Drugs - Oseltamivir
Treatment: Drugs - Placebo
Experimental: A: MHAA4549A 3600 mg + Oseltamivir - Participants will receive a single low IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
Experimental: B: MHAA4549A 8400 mg + Oseltamivir - Participants will receive a single high IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
Placebo comparator: C: Placebo + Oseltamivir - Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1 and standard oseltamivir therapy (75 or 150 mg BID) for minimum of 5 days.
Treatment: Drugs: MHAA4549A
Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
Treatment: Drugs: Oseltamivir
Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
Treatment: Drugs: Placebo
Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Adverse Events
Query!
Assessment method [1]
0
0
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Query!
Timepoint [1]
0
0
From randomization up to 60 days
Query!
Primary outcome [2]
0
0
Number of Participants With Anti-Therapeutic Antibodies (ATA) to MHAA4549A During and Following Administration of MHAA4549A
Query!
Assessment method [2]
0
0
Reported are the number of participants positive for ATAs at baseline, the number of participants with treatment-induced ATAs and the number of participants with treatment-enhanced ATAs.
Query!
Timepoint [2]
0
0
From randomization up to 60 days
Query!
Primary outcome [3]
0
0
Time to Normalization of Respiratory Function
Query!
Assessment method [3]
0
0
The time to normalization of respiratory function was defined as the time to removal of the participant from oxygen (O2) supplementation in order to maintain a blood oxygen saturation level (SpO2) equal to or greater than 95% as measured by pulse oximetry.
Query!
Timepoint [3]
0
0
From randomization up to 60 days
Query!
Secondary outcome [1]
0
0
Percentage of Participants by Clinical Status Using a Categorical Ordinal Outcome
Query!
Assessment method [1]
0
0
The clinical status of participants was defined by five mutually exclusive categories: 1. Death; 2. In the Intensive Care Unit (ICU); 3. Non-ICU hospitalization, requiring supplemental oxygen (O2); 4. Non-ICU hospitalization, not requiring supplemental oxygen (O2); 5. Not hospitalized.
Query!
Timepoint [1]
0
0
Days 1-7, 14 and 30
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Clinical Failure
Query!
Assessment method [2]
0
0
Clinical failure after 24 hours post-infusion of study drug was defined as progression to increased O2 requirement defined by an increase in oxygen supplementation from low flow oxygen (i.e., 2-6 liters per minute \[L/min\]) to high flow oxygen (i.e., \> 6 L/min) or from oxygen supplementation alone to any positive pressure ventilation (PPV) or extracorporeal membrane oxygenation (ECMO), progression to ICU, prolonged ventilation or O2 support defined by \> 2 weeks, or death.
Query!
Timepoint [2]
0
0
24 hours after end of infusion (infusion duration = approximately 120 minutes) up to Day 60
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Clinical Resolution of Abnormal Vital Signs
Query!
Assessment method [3]
0
0
Description: Clinical resolution of abnormal vital signs was defined as meeting three out of five of the following criteria: 1. SpO2 = 95% without supplemental O2; 2. Respiratory rate \< 24 breaths per minute without supplemental O2; 3. Core temperature \< 37.2 Celsius (C) immediately prior to receipt of any antipyretic drug, and at least 6-8 hours from the last dose of antipyretic or core temperature \> 36 C in participants who are initially hypothermic; 4. Heart rate (HR) \< 100 beats/minute; 5. Systolic blood pressure (SBP) \>90 mmHg. Reported here is the percentage of participants who had clinical resolution of at least three out of five abnormal vital signs by the end of study.
Query!
Timepoint [3]
0
0
From randomization up to 60 days
Query!
Secondary outcome [4]
0
0
Percentage of Participants Who Died Due to Any Cause
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Days 14, 30 and 60
Query!
Secondary outcome [5]
0
0
Area Under Viral Load-Time Curve (AUEC ) of Influenza A Virus
Query!
Assessment method [5]
0
0
Influenza A viral load was measured by quantitative polymerase chain reaction (qPCR) in nasopharyngeal samples at multiple time points during the study. AUEC is the area under the viral load-time curve expressed as log10 (viral particles/milliliter x hour) = log10 (vp/mL x hour).
Query!
Timepoint [5]
0
0
Immediately prior to MHAA4549A infusion and oseltamivir dosing on Day 1, immediately prior to oseltamivir dosing on Days 2 to 10, Days 14, 20, 25, 30, on day of discharge from hospital (up to Day 60), and at study completion (Day 60)
Query!
Secondary outcome [6]
0
0
Peak Influenza A Viral Load
Query!
Assessment method [6]
0
0
Influenza A viral load was measured by qPCR in nasopharyngeal samples at multiple time points during the study. Reported here is the peak Influenza A viral load expressed as log10 vp/mL.
Query!
Timepoint [6]
0
0
Immediately prior to MHAA4549A infusion and oseltamivir dosing on Day 1, immediately prior to oseltamivir dosing on Days 2 to 10, Days 14, 20, 25, 30, on day of discharge from hospital (up to Day 60), and at study completion (Day 60)
Query!
Secondary outcome [7]
0
0
Duration of Viral Shedding
Query!
Assessment method [7]
0
0
Influenza A viral load was measured by qPCR in nasopharyngeal samples at multiple time points during the study. Reported here is the duration of viral shedding.
Query!
Timepoint [7]
0
0
Immediately prior to MHAA4549A infusion and oseltamivir dosing on Day 1, immediately prior to oseltamivir dosing on Days 2 to 10, Days 14, 20, 25, 30, on day of discharge from hospital (up to Day 60), and at study completion (Day 60)
Query!
Secondary outcome [8]
0
0
Duration of Hospitalization
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
From randomization up to 60 days
Query!
Secondary outcome [9]
0
0
Duration of Intensive Care Unit (ICU) Stay
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
From randomization up to 60 days
Query!
Secondary outcome [10]
0
0
Percentage of Participants Using Antibiotics for Respiratory Infections
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
From randomization up to 60 days
Query!
Secondary outcome [11]
0
0
Percentage of Participants With Secondary Complications of Influenza
Query!
Assessment method [11]
0
0
The following were considered secondary complications of influenza: pneumonia, including hospital-acquired pneumonia (HAP) and ventilation-acquired pneumonia (VAP), exacerbations of chronic lung disease, myocarditis, acute respiratory distress syndrome (ARDS), otitis media, or other related complications.
Query!
Timepoint [11]
0
0
From randomization up to 60 days
Query!
Secondary outcome [12]
0
0
Percentage of Participants Readmitted to Hospital Due to Any Cause
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Days 30 and 60
Query!
Secondary outcome [13]
0
0
Duration of Ventilation
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
From randomization up to 60 days
Query!
Secondary outcome [14]
0
0
Area Under Serum Concentration-Time Curve From Time 0 to Infinity (AUC ) of MHAA4549A
Query!
Assessment method [14]
0
0
AUC0-inf is reported as day\*microgram/milliliter (day\*mcg/mL).
Query!
Timepoint [14]
0
0
30 minutes (min) before & 60 min after end of MHAA4549A infusion (infusion duration = 120 min) on Day 1; immediately prior to oseltamivir dose on Days 2, 3, 5, 7; on Days 14, 30; on day of discharge (up to Day 60); at study completion (Day 60)
Query!
Secondary outcome [15]
0
0
Maximum Serum Concentration (Cmax ) of MHAA4549A
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
30 min before & 60 min after end of MHAA4549A infusion (infusion duration = 120 min) on Day 1; immediately prior to oseltamivir dose on Days 2, 3, 5, 7; on Days 14, 30; on day of discharge (up to Day 60); at study completion (Day 60)
Query!
Secondary outcome [16]
0
0
Elimination Half-Life (Terminal t1/2) of MHAA4549A
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
30 min before & 60 min after end of MHAA4549A infusion (infusion duration = 120 min) on Day 1; immediately prior to oseltamivir dose on Days 2, 3, 5, 7; on Days 14, 30; on day of discharge (up to Day 60); at study completion (Day 60)
Query!
Secondary outcome [17]
0
0
Observed Clearance (CL-obs) of MHAA4549A
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
30 min before & 60 min after end of MHAA4549A infusion (infusion duration = 120 min) on Day 1; immediately prior to oseltamivir dose on Days 2, 3, 5, 7; on Days 14, 30; on day of discharge (up to Day 60); at study completion (Day 60)
Query!
Secondary outcome [18]
0
0
Observed Steady State Volume of Distribution (Vss_obs) of MHAA4549A
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
30 min before & 60 min after end of MHAA4549A infusion (infusion duration = 120 min) on Day 1; immediately prior to oseltamivir dose on Days 2, 3, 5, 7; on Days 14, 30; on day of discharge (up to Day 60); at study completion (Day 60)
Query!
Eligibility
Key inclusion criteria
* Diagnosis of influenza A where a Sponsor-approved influenza test is used as an aid in diagnosis. A Sponsor-approved influenza test includes: Influenza antigen test or Influenza polymerase chain reaction (PCR) test
* One of the following markers of severity within 24 hours of admission: requirement for O2 supplementation to maintain SpO2 greater than (>) 92 %; or requirement for Positive Pressure Ventilation (PPV)
* A negative urine or serum pregnancy test for women of childbearing potential within 2 days prior to study treatment
* Participants of reproductive potential must agree to use acceptable contraceptive measures as per the protocol as a minimum, and local guidelines, if more stringent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Pregnant or lactating women, or women who intend to become pregnant during the study
* Hypersensitivity to monoclonal antibodies or any constituents (sodium succinate, sucrose, polysorbate 20) of study drug
* Hypersensitivity to the active substance or to any excipients of oseltamivir
* Investigational therapy within the 30 days prior to study treatment
* Received prior therapy with any anti-influenza monoclonal antibody therapy (including MHAA4549A) within 8 months prior to study treatment
* Current treatment (within 7 days of dosing) with probenecid, amantadine or rimantidine
* Participants who have taken more than a total of 6 doses (3 doses for peramivir) of anti-influenza therapy (e.g., oseltamivir, zanamivir, laninamivir, peramivir) in the period from onset of symptoms and prior to study treatment
* Admission >48 hours prior to study treatment
* Onset of influenza symptoms (including fever, chills, malaise, dry cough, loss of appetite, myalgias, coryza, or nausea) >5 days prior to study treatment
* Positive influenza B or influenza A + B infection within 2 weeks prior to study treatment
* High probability of mortality in the next 48 hours as determined by the investigator
* Participants requiring home or baseline oxygenation therapy
* Participants with history of chronic lung disease with a documented SpO2 less than (<) 95% off oxygen
* Participants on chronic dose of corticosteroids exceeding 10 milligrams per day (mg/day) of prednisone or equivalent steroid dose for duration of greater than 14 days within 30 days of entry into study
* Participants with the following significant immune suppression: bone marrow or solid organ transplant in the previous 12 months; cancer chemotherapy in the previous 12 months, HIV infection with most recent Cluster of Differentiation 4 (CD4) <200 cells per milliliter (cells/mL), or other significant immune suppression as determined by the investigator in discussion with the Sponsor Medical Monitor
* Participants on extracorporeal membrane oxygenation (ECMO) at time of randomization
* Any disease or condition that would, in the opinion of the site investigator or Sponsor, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/01/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/05/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
168
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Brussels
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Bruxelles
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Leuven
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Mont-godinne
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
MG
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
RS
Query!
Country [7]
0
0
Brazil
Query!
State/province [7]
0
0
SP
Query!
Country [8]
0
0
Bulgaria
Query!
State/province [8]
0
0
Gabrovo
Query!
Country [9]
0
0
Bulgaria
Query!
State/province [9]
0
0
Plovdiv
Query!
Country [10]
0
0
Bulgaria
Query!
State/province [10]
0
0
Ruse
Query!
Country [11]
0
0
Bulgaria
Query!
State/province [11]
0
0
Sevlievo
Query!
Country [12]
0
0
Bulgaria
Query!
State/province [12]
0
0
Sofia
Query!
Country [13]
0
0
Bulgaria
Query!
State/province [13]
0
0
Varna
Query!
Country [14]
0
0
Bulgaria
Query!
State/province [14]
0
0
Veliko Tarnovo
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Alberta
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
British Columbia
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
New Brunswick
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
Chile
Query!
State/province [20]
0
0
Temuco
Query!
Country [21]
0
0
Chile
Query!
State/province [21]
0
0
Vina del Mar
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Brno
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Hradec Kralove
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Liberec
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Ostrava
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Praha 10
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Argenteuil
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Clermont-ferrand
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Dijon
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Garches
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
La Roche Sur Yon
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Lille
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Limoges
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Nancy
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Nice
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Paris
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Strasbourg
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Tours
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Frankfurt
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Heidelberg
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Koeln
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Mainz
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Tuebingen
Query!
Country [44]
0
0
Hong Kong
Query!
State/province [44]
0
0
Hong Kong
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Kistarcsa
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Veszprém
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Vác
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Zalaegerszeg
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Afula
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Beer-Sheva
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Holon
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Jerusalem
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Nahariya
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Nazareth
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Petah Tikva
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Rehovot
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Tel Aviv
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Tel Hashomer
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Zefat
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Basilicata
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Emilia-Romagna
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Lazio
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Lombardia
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Sardegna
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Busan
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Incheon
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Seoul
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Wonju
Query!
Country [69]
0
0
Mexico
Query!
State/province [69]
0
0
Guadalajara
Query!
Country [70]
0
0
Mexico
Query!
State/province [70]
0
0
Mexico, Distrito Federal
Query!
Country [71]
0
0
Mexico
Query!
State/province [71]
0
0
Monterrey
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Tijuana
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Xalapa-enriquez
Query!
Country [74]
0
0
Netherlands
Query!
State/province [74]
0
0
'S Hertogenbosch
Query!
Country [75]
0
0
Netherlands
Query!
State/province [75]
0
0
Apeldoorn
Query!
Country [76]
0
0
Netherlands
Query!
State/province [76]
0
0
Leiden
Query!
Country [77]
0
0
Netherlands
Query!
State/province [77]
0
0
Nijmegen
Query!
Country [78]
0
0
Netherlands
Query!
State/province [78]
0
0
Rotterdam
Query!
Country [79]
0
0
Netherlands
Query!
State/province [79]
0
0
Utrecht
Query!
Country [80]
0
0
Netherlands
Query!
State/province [80]
0
0
Zwolle
Query!
Country [81]
0
0
New Zealand
Query!
State/province [81]
0
0
Auckland
Query!
Country [82]
0
0
New Zealand
Query!
State/province [82]
0
0
Christchurch
Query!
Country [83]
0
0
New Zealand
Query!
State/province [83]
0
0
Tauranga
Query!
Country [84]
0
0
Peru
Query!
State/province [84]
0
0
Cusco
Query!
Country [85]
0
0
Peru
Query!
State/province [85]
0
0
Cuzco
Query!
Country [86]
0
0
Peru
Query!
State/province [86]
0
0
La Victoria
Query!
Country [87]
0
0
Peru
Query!
State/province [87]
0
0
LIma
Query!
Country [88]
0
0
Peru
Query!
State/province [88]
0
0
Lima
Query!
Country [89]
0
0
Peru
Query!
State/province [89]
0
0
Piura
Query!
Country [90]
0
0
Peru
Query!
State/province [90]
0
0
San Juan de Miraflores
Query!
Country [91]
0
0
Peru
Query!
State/province [91]
0
0
Trujillo
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Lublin
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Szczecin
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Torun
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Lódz
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Chelyabinsk
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Engels
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
St.Petersburg
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
Vladivostok
Query!
Country [100]
0
0
South Africa
Query!
State/province [100]
0
0
Parktown West
Query!
Country [101]
0
0
South Africa
Query!
State/province [101]
0
0
Pretoria
Query!
Country [102]
0
0
South Africa
Query!
State/province [102]
0
0
Worcester
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Barcelona
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Cantabria
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Islas Baleares
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Granada
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Madrid
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Tarragona
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Valencia
Query!
Country [110]
0
0
Sweden
Query!
State/province [110]
0
0
Goteborg
Query!
Country [111]
0
0
Sweden
Query!
State/province [111]
0
0
Göteborg
Query!
Country [112]
0
0
Sweden
Query!
State/province [112]
0
0
Mamö
Query!
Country [113]
0
0
Sweden
Query!
State/province [113]
0
0
Umeå
Query!
Country [114]
0
0
Taiwan
Query!
State/province [114]
0
0
Kaohsiung
Query!
Country [115]
0
0
Taiwan
Query!
State/province [115]
0
0
New Taipei
Query!
Country [116]
0
0
Taiwan
Query!
State/province [116]
0
0
Taipei
Query!
Country [117]
0
0
Taiwan
Query!
State/province [117]
0
0
Taoyuan City
Query!
Country [118]
0
0
Ukraine
Query!
State/province [118]
0
0
Kyiv
Query!
Country [119]
0
0
Ukraine
Query!
State/province [119]
0
0
Odesa
Query!
Country [120]
0
0
Ukraine
Query!
State/province [120]
0
0
Poltava
Query!
Country [121]
0
0
Ukraine
Query!
State/province [121]
0
0
Zhytomyr
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Birmingham
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Glasgow
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Leeds
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
London
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
Southampton
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
Stoke-On-Trent
Query!
Country [128]
0
0
United Kingdom
Query!
State/province [128]
0
0
Taunton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Genentech, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a randomized, double-blind, placebo-controlled study that will investigate the safety and clinical activity of a single intravenous (IV) dose of MHAA4549A in adult participants hospitalized with severe influenza A in combination with oseltamivir versus a comparator arm of placebo with oseltamivir.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02293863
Query!
Trial related presentations / publications
Lim JJ, Nilsson AC, Silverman M, Assy N, Kulkarni P, McBride JM, Deng R, Li C, Yang X, Nguyen A, Horn P, Maia M, Castro A, Peck MC, Galanter J, Chu T, Newton EM, Tavel JA. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00352-20. doi: 10.1128/AAC.00352-20. Print 2020 Jun 23.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/63/NCT02293863/Prot_SAP_000.pdf
Statistical analysis plan
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/63/NCT02293863/Prot_SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT02293863
Download to PDF